ArticleJACC. Case reports2026
25-Year Evolution of Apical Hypertrophic Cardiomyopathy in a Professional Athlete.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death in young athletes. Risk stratification and disease evolution in athletes who continue competitive sport, particularly in apical phenotypes, remain incompletely defined. CASE SUMMARY: A 14-year-old academy football player was diagnosed with subclinical HCM during preparticipation screening and elected to continue competing despite contemporaneous guideline restrictions. Over 25 years of follow-up, he progressed to apical HCM with late gadolinium enhancement and mild ventricular ectopy but maintained excellent functional capacity and remained asymptomatic. After transferring to a lower-tier club, both palpitations and ventricular ectopy decreased. He completed a long professional career and developed an apical aneurysm shortly before retiring. DISCUSSION: This case highlights the complexity of exercise counseling in HCM and is consistent with contemporary guideline-supported, individualized decision-making, as it illustrates that selected low-risk athletes may tolerate long-term competition. The extended follow-up highlights the long-term natural history of apical HCM in an athlete and underscores persistent uncertainties regarding phenotype-specific risk modifiers, including myocardial fibrosis and apical aneurysm formation. TAKE-HOME MESSAGE: Personalized, shared decision-making is essential in athletes with HCM, and refined risk-stratification models are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.